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deployment of long coronary scaffolds/stents (28  mm in 
length), BRS provides better conformability compared with 
MPS.
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Abbreviations
AMI  Acute myocardial infarct
BRS  Bioresorbable scaffolds (BRS)
CABG  Coronary artery bypass graft
CoCr- EES  Cobalt chromium- everolimus eluting stent
Cv  Curvature
CVA  Cerebrovascular accident
DES  Drug eluting stent
LAD  Left anterior descending artery
LCX  Left circumflex artery
MLD  Minimal luminal diameter
MPS  Metallic platform stent
PCI  Percutaneous coronary intervention
PLLA  Poly-l-lactic acid
QCA  Quantitative coronary angiography
RCA  Right coronary artery
RVD  Reference vessel diameter
STEMI  ST Elevation myocardial infarct
Introduction
The everolimus-eluting bioresorbable scaffolds (BRS) 
represented a novel change in the treatment of coronary 
artery lesions. The BRS is composed of a poly-l-lactic 
acid (PLLA)—based platform. Besides the ability to have 
complete strut resorption at 36 months, there are several 
Abstract The aim of this study was to determine if there 
are significant differences in curvature of the treated ves-
sel after the deployment of a polymeric BRS or MPS in 
long lesions. The impact of long polymeric bioresorbable 
scaffolds (BRS) compared with metallic platform stents 
(MPS) on vessel curvature is unknown. This retrospec-
tive study compares 32 patients who received a single 
everolimus-eluting BRS with 32 patients treated with a 
single MPS of 28  mm. Quantitative coronary angiogra-
phy (QCA) was used to evaluate curvature of the treatment 
and peri-treatment region before and after percutaneous 
coronary intervention (PCI). Baseline demographic and 
angiographic characteristics were similar between the BRS 
and MPS groups. Pretreatment lesion length was 22.19 
versus 20.38  mm in the BRS and MPS groups respec-
tively (p = 0.803). After treatment, there was a decrease in 
median diastolic curvature in the MPS group (from 0.257 
to 0.199  cm−1, p = 0.001). A similar trend was observed 
in the BRS group but did not reach statistical significance 
(median diastolic curvature from 0.305 to 0.283  cm−1, 
p = 0.056). Median Percentage relative change in diastolic 
curvature was lower in the BRS group compared with the 
MPS group (BRS vs. MPS: 7.48 vs. 29.4%, p = 0.013). By 
univariate analysis, use of MPS was an independent pre-
dictor of change in diastolic curvature (p = 0.022). In the 
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potential benefits of BRS including no trigger for throm-
bosis after resorption and restoration of vasoreactivity [1]. 
Typically, implantation of hard metallic implants straight-
ens the coronary artery and thus modifies its curvature. 
A previous computational study demonstrated that after 
implantation of a metallic implant in a coronary artery, 
the curvature of the stent edges alters significantly which 
correlate to the changes in shear stress distribution and 
potentially with the neointimal proliferation pattern [2]. As 
implantation of coronary stents/scaffolds can alter blood 
rheology especially at the inflow and outflow edge of the 
stents, the vessel distortion post device implantation may 
contribute to early and late stent failure such as pertaining 
to stent fracture. Geometric changes in the arteries post 
implantation are largely determined by the conformability 
of the stent [3]. The conformability of the stent has been 
described as the flexibility of a stent in its expanded state 
with adaptation to the natural shape of the vessel. A higher 
conformability of the stent is associated with less potential 
for vessel distortion and trauma [4].
Previous studies using BRS in short lesions demonstrate 
better conformability and favorable clinical outcomes com-
pared to MPS in the acute setting [5, 6]. In the study by 
Gomez Lara et al., the acute change in curvature and angu-
lation as quantified by quantitative coronary angiographic 
analysis was decreased in BRS compared to MPS [6] and 
was shown to recover on follow up [7]. This effect may 
be more pronounced and more relevant in a long lesion in 
either the coronary or peripheral arterial system. However, 
the acute effects of its implantation on vessel geometry in 
long coronary lesions are yet to be investigated. The aim of 
this study was to determine if there are any significant dif-
ferences in terms of curvature of the treated vessel after the 
deployment of a polymeric scaffold device in long lesions 
and compare this to a MPS.
Methods
Study design, population, and treatment device
This is a non-randomized, 2-arm, retrospective study per-
formed with patients from the BVS Expand and BVS 
STEMI First registries that received a everolimus eluting 
BRS (ABSORB-BVS, Abbott Vascular, Santa Clara, CA, 
USA) compared with a subset of historical controls from 
the same institutional registries (X-SEARCH) who received 
a cobalt chromium- everolimus eluting stent (CoCr-EES; 
 XIENCER stent, Abbott Vascular, Santa Clara, CA, US).
In brief, the common inclusion criteria for this study are 
patients who had received a single BRS or CoCr EES that 
are 28 mm in length in long coronary lesions. The patients 
in the BRS group are selected from the BVS Expand [8] 
and BVS STEMI [9] registries which are single centre 
prospective observational registries conducted at Thorax 
Centre, Erasmus Medical Centre that evaluates the long 
term safety and performance of the BRS-absorb coronary 
stent in routine clinical practice post market registration. 
Informed, written consent was obtained from the patients 
before they undergo any procedure. The lesions are also 
more complex with more bifurcations and calcified lesions. 
From the X-SEARCH registry, patients with similar angio-
graphic characteristics were selected for this study [10].
The BRS-Absorb vascular scaffold is a balloon-expand-
able device, consisting of a polymer backbone of PLLA 
coated with a thin layer of a 1:1 mixture of an amorphous 
matrix of PLLA polymer containing 100  μg/cm2 of the 
antiproliferative drug everolimus. The implant is radiolu-
cent but has two platinum markers at each edge that allow 
visualization on angiography and other imaging modali-
ties. Physically the scaffold has struts with an approximate 
thickness of 150 µm, which are arranged as in-phase zigzag 
hoops linked together by three longitudinal links (Fig. 1a).
The metallic platform of the everolimus-eluting 
 XIENCER family stent (EES) is composed of a cobalt chro-
mium (CoCr) alloy. The platform has a design similar to 
the Absorb platform and consists of serpentine rings con-
nected by links fabricated from a single piece (Fig.  1b). 
The metallic platforms of the CoCr EES are constructed by 
a strut thickness of 81 µm each [11].
Treatment procedure
Lesions treated with the BRS were implanted according to 
the procedural steps in line with the accepted recommenda-
tions at the time of the study. Predilation with either a semi-
compliant or non-compliant balloon was highly encour-
aged. The BRS was implanted at a pressure not exceeding 
the rated burst pressure (16 atm). Post-dilation with either a 
semi-compliant or non-compliant balloon was performed at 
the discretion of the operator. Patients were prescribed with 
standard guideline recommended medical therapy includ-
ing at least 12 months’ duration of dual antiplatelet therapy 
and antianginal therapy when appropriate.
Quantitative coronary angiography (QCA) evaluation
Angiographic views with minimal foreshortening of the 
lesion and limited overlap with other vessels were used 
whenever possible for all phases of the treatment: prepro-
cedural angiography, and after obtaining final result [12]. 
Comparison between pre and post treatment, were per-
formed in matched angiographic views of 10° or less. The 
2-dimensional (2D) angiograms were analyzed with the 
CASS 5.10 analysis system (Pie Medical BV, Maastricht, 
the Netherlands). In each patient, the treated region and the 
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peri-treated regions (defined by 5 mm proximal and distal 
to the device edge) were analyzed. The computer defined 
minimal luminal diameter, reference diameter obtained by 
an interpolated method, and percentage diameter stenosis 
in the post procedure angiogram.
The definition of “Curvature” is the infinitesimal rate 
of change in the tangent vector at each point of the cen-
terline. This measurement has a reciprocal relationship to 
the radius of the perfect circle defined by the curve at each 
point. The curvature of the vessel is calculated as 1/radius 
of the circle in  cm−1, with a research program installed 
in the QCA Analysis software (CASS 5.10, Pie Medical 
Imaging) [13]. The segment of interest was defined as the 
stented/scaffolded length. To enable analysis of curvature 
in the same anatomical region, the scaffold position was 
superimposed on the preprocedural angiogram (Fig.  2). 
The software automatically detects the lumen contours of 
the selected segment and configures the centerline. Three 
points are then defined according to the centerline: one at 
the proximal, one at the distal, and one at the center of the 
defined segment. Next, a perfect circle is drawn through 
these points, calculating the radius of the circle and the cur-
vature value. Prior to and after the procedure, the curvature 
of the segment of interest was repeatedly measured both 
during systole and diastole. Percentage relative change in 
curvature (Cv) was calculated as % (postCv–preCv)/preCv 
in the respective cardiac phases. Cyclic changes in vessel 
curvature were estimated as differences between systole 
and diastole at both pre-treatment and post-treatment.
Statistical analysis
The Kolmogorov–Smirnov test was used to evaluate the 
normality assumptions of all continuous variables. Descrip-
tive statistical analysis was performed with continuous var-
iables expressed as median (interquartile range) and with 
categorical variables presented as counts (%). For compari-
son between groups, Mann–Whitney U test were used for 
the continuous variables. The Chi square test has been used 
to assess differences in categorical variables. Pre and post 
treatment comparisons within groups were assessed with 
Wilcoxon signed rank tests. Because the curvature, cyclic 
changes of curvature, and difference of curvature between 
pre- and post-treatment did not have a normal distribution, 
a log transformation was performed to achieve a normal 
distribution. A univariate analysis was performed between 
curvature and angulation changes with baseline demo-
graphic and angiographic variables. Variables that were 
found to be significant at the univariate level were tested 
with a multivariate linear regression model. (The thresh-
olds for entry into and removal from the model were 0.1.) 
All statistical tests were carried out at the 5% level of sig-
nificance. All analysis was performed by SPSS version 21 
(SPSS, Inc., Chicago Illinois).
Results
The baseline clinical and angiographic characteristics are 
shown in Table 1. A total of 64 patients were involved in 
this study of which 32 were treated with the BRS and 32 
with the MPS. A flow chart summarizing patient selection 
is shown in Fig. 3. There was no difference in median age 
(BRS vs. MPS: 59.6 vs. 64.9 years, p = 0.453), gender or 
clinical presentation between the 2 device groups. There 
were no significant differences in the cardiovascular risk 
factors.
The left anterior descending artery was the most com-
monly treated vessel in the study population. Lesion cal-
cification and complexity were similar between the two 
groups (Table 1). Procedural data are as shown in Table 1. 
Lesions treated with BRS were predilated more frequently 
and at higher pressures compared to the lesions treated 
with metallic stents. Postdilation rates were similar. The 
pre treatment region length was 21.38  mm (17.67–25.58) 
in the overall group. There were no significant differences 
in reference vessel diameter, minimal lumen diameter and 
Fig. 1  a Bioresorbable scaffold: The second generation ABSORB-
BVS (Abbott Vascular, Santa Clara, CA, USA) has a strut thickness 
of 150  μm, consisting of in-phase zigzag hoops linked by bridges. 
The device is radiolucent but has two radioopaque platinum mark-
ers at each proximal and distal edge that facilitate ease of visualiza-
tion on angiography. b Cobalt chromium everolimus- eluting stent 
(CoCr EES-  XIENCER, Abbott Vascular, Santa Clara, CA, US): The 
 XIENCER are the metal platform stents and consist of a metallic plat-
form made of cobalt chromium alloy. The struts are serpentine rings 
connected by links fabricated from a single piece. The  XIENCER is 
covered by an everolimus coating
1866 Int J Cardiovasc Imaging (2017) 33:1863–1871
1 3
percentage diameter stenosis in both groups. Pretreat-
ment curvature was similar between the BRS and MPS 
groups in both systole and diastole phases [systole: 0.290 
(0.155–0.639)  cm−1 vs. 0.283 (0.125–0.519) respectively, 
p = 0.803 and diastole: 0.305 (0.193–0.580)  cm−1 vs. 0.257 
(0.151–0.518)  cm−1 respectively, p = 0.803].
Geometric changes within and between groups
Table  2 shows the changes in curvature in both systole 
and diastole of the treated vessel in the BRS and MPS 
groups. After implantation of MPS, there was a signifi-
cant decrease in median diastolic curvature (from 0.257 
to 0.199  cm−1, p = 0.001) and median systolic curvature 
(0.283–0.194  cm−1, p < 0.001) representing a percentage 
reduction of 16.0 and 28.6% respectively. Following an 
absorb scaffold implantation, there was a trend towards a 
decrease in the median diastolic curvature (from 0.305 to 
0.283 cm−1, p = 0.056) and median systolic curvature (from 
0.290 to 0.282 cm−1, p = 0.061) which trends towards sig-
nificance. As a result, the diastolic curvature was signifi-
cantly higher in the BRS compared with the MPS group 
post treatment [BRS vs. MPS; 0.283  cm−1 (0.150–0.541) 
vs. 0.199  cm−1 (0.089–0.357), p = 0.035] (Fig.  4). Post 
treatment, Percentage relative reduction in curvature was 
also smaller in the BRS group compared with MPS group 
in both the diastole and systole phases [BRS vs. MPS; 7.48 
vs. 29.4%, p = 0.013; 9.04 vs. 28.2%, p = 0.010 respec-
tively]. Cyclic changes in curvature (i.e. between systole 
and diastole) were similar between the BRS and the MPS 
(p = 0.271).
Predictive factors of modifying curvature
In univariate analysis, the use of MPS predicts a greater 
reduction in curvature with a coefficient of 23.33 (95% con-
fidence interval 3.81–42.85, p = 0.02).
Discussion
In summary, the major finding of this study showed that in 
the deployment of long coronary devices (28 mm in length), 
BRS showed a non-significant decrease in curvature in the 
post treated vessel compared with a significant reduction in 
curvature of the treated vessel with deployment of a MPS. 
Fig. 2  Curvature Analysis 
of the BRS and MPS: curva-
ture analysis before and after 
deployment of a BRS (Fig. 2a, 
b) and a MPS (Fig. 2c, d). 
After implantation of a BRS, 
the curvature changed from 
0.58 to 0.49 cm−1 whereas after 
the MPS was implanted, the 
curvature changed from 0.85 to 
0.23 cm−1. BRS bioresorbable 
scaffold, MPS metallic platform 
stent
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Use of MPS was an independent predictor of vessel curva-
ture change post deployment.
Stent conformability is dependent on both the material 
and design of the stent and differs between the commercial 
devices that are available [14–16]. An open cell stent design 
would have higher conformability compared to a closed 
cell design. The difference in curvature post treatment 
between BRS and MPS could be attributed to the difference 
Table 1  Baseline clinical and 
angiographic characteristics
Values are presented as number (%) or median (interquartile range)
AMI acute myocardial infarct, BRS bioresorbable scaffold, CABG coronary artery bypass graft, CVA cer-
ebrovascular accident, LAD left anterior descending artery, LCX left circumflex artery, MLD minimal lumi-
nal diameter, MPS metallic platform stent, PCI percutaneous coronary intervention, RCA right coronary 
artery, RVD reference vessel diameter, STEMI ST elevation myocardial infarct
BRS (N = 32) MPS (N = 32) p value
Age (years) 59.6 (52.5, 67.8) 64.9 (57.7, 70.7) 0.453
Men 22 (68.8) 22 (68.8) 1.000
Hypertension 18 (56.2) 20 (62.5) 0.611
Hypercholesterolemia 15 (46.9) 17 (53.1) 0.617
Diabetes mellitus 5 (15.6) 8 (25.0) 0.351
Smoker (active) 12 (37.5) 7 (21.9) 0.391
Family history
 Previous CVA 2 (6.2) 2 (6.2) 1.000
Previous AMI 6 (18.8) 12 (37.5) 0.095
Previous PCI 5 (15.6) 9 (28.1) 0.226
Previous CABG 0 0
Clinical presentation
 Stable or silent angina 10 (31.3) 18 (56.3) 0.074
 Unstable angina 1 (3.1) 4 (12.5) 0.355
 STEMI 4 (12.5) 0 0.155
 NSTEMI 17 (53.1) 9 (28.1) 0.074
 Other 0 1 (3.1) 1.000
Target vessel 0.857
 LAD 15 (46.9) 13 (40.6)
 LCX 6 (18.8) 6 (18.8)
 RCA 11 (34.4) 13 (40.6)
 RVD (mm) 2.90 (2.49, 3.18) 2.91 (2.29, 3.26) 0.803
 MLD (mm) 0.92 (0.77, 1.57) 1.20 (0.75, 1.55) 0.453
 Diameter stenosis (%) 60.00 (47.25, 72.75) 56.00 (46.00, 76.75) 0.452
Bifurcation 12 (37.5) 7 (21.9) 0.274
AHA type 0.149
 A 2 (6.3) 0
 B1 19 (59.4) 14 (43.8)
 B2 6 (18.8) 13 (40.6)
 C 5 (15.6) 5 (15.6)
Calcification
 Mild 19 (59.4) 12 (37.5)
 Moderate/severe 13 (40.6) 20 (62.5)
Pre-treatment region length (mm) 22.19 (17.67, 25.08) 20.38 (17.05, 25.75) 0.803
Procedural details
 Predilation performed 29 18 0.004
 Predilation balloon diameter 2.50 (2.50, 2.50) 2.00 (2.00, 2.50) 0.03
 Postdilation 18 13 0.317
 Postdilation diameter 3.00 (2.94, 3.50) 3.50 (2.75, 4.00) 0.253
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in underlying material composition of the devices in that a 
polymeric bioresorbable scaffold has better conformability 
to vessel geometry compared to metallic stents. In a study 
evaluating the bending stiffness of the BRS compared to 
the MPS in-vitro, the maximum compressive load of a BRS 
from ABSORB COHORT B trial was significantly lower 
compared to the  XIENCER stent which signifies better con-
formability of the BRS (Fig.  5) [17]. This is despite the 
fact that the strut thickness of the ABSORB Cohort B stent 
is thicker than that of the  XIENCER stent (strut thickness 
Fig. 3  Flow chart of patient 
selection. BRS bioresorbable 
scaffold, CTO chronic total 
occlusion, MPS metallic plat-
form stents, STEMI ST eleva-
tion myocardial infarct
Table 2  Changes in curvature of the study population
Values are presented as numbers or median (interquartile range)
a For BRS, the p values for comparison between pre and post curvature for systole and diastole are 0.061 and 0.056 respectively. For MPS, the p 
values for comparison between pre and post curvature for systole and diastole are <0.001(*) and 0.001(*) respectively
BRS bioresorbable scaffold, MPS metallic platform stent
BRS (N = 32) MPS (N = 32) p value
Pre-treatment curvature  (cm−1)
 Systole 0.290 (0.155, 0.639) 0.283 (0.125, 0.519) 0.648
 Diastole 0.305 (0.193, 0.580) 0.257 (0.151, 0.518) 0.460
Post-treatment curvature  (cm− 1)
 Systole 0.282 (0.147, 0.549) 0.194 (0.097, 0.407) 0.077
 Diastole 0.283 (0.150, 0.541) 0.199 (0.089, 0.357) 0.035
Percentage reduction in curvature post-pretreatmenta
 Systole 2.76 28.6*
 Diastole 7.21 16.0*
Absolute reduction in curvature  (cm−1)
 Systole 0.024 (0.015, 0.087) 0.064 (0.010, 0.230) 0.034
 Diastole 0.021 (0.025, 0.098) 0.090 (0.011, 0.192) 0.066
Percentage relative change in curvature  (cm−1)
 Systole −9.035 (−22.128, 7.911) −28.17 (−46.22, −6.64) 0.010
 Diastole −7.484 (−23.193, 8.355) −29.43 (−50.31, −3.55) 0.013
Pre-treatment cyclic change in curvature  (cm−1) −0.021 (−0.072, 0.061) 0.002 (−0.086, 0.096) 0.398
Post-treatment cyclic change in curvature  (cm−1) −0.026 (−0.054, 0.023) −0.041 (−0.04, 0.125) 0.271
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152.4 vs. 81.3 µm). A previous study had shown that the 
use of relatively shorter (18  mm) BRS and MPS devices 
modify baseline vessel curvature but the change was more 
marked in the MPS compared with the BRS [6]. In this 
study, the median pretreatment lesion length was 16.3 and 
16.8 mm in the BRS and MPS groups respectively which 
are comparatively shorter compared to our study popula-
tion. To our knowledge, this is the first in vivo study that 
shown that BRS does not affect the curvature of the treated 
vessel significantly in the deployment of long scaffolds. 
This might be of useful significance as we treat longer 
lesions with overlap scaffold required.
Though OCT has been widely described in exist-
ing methodology [18–21] to evaluate scaffold perfor-
mance, OCT by itself is not able to measure curvature 
of the vessel, whereas QCA is available pre and post in 
almost all patients. From fluid dynamics and the result-
ing shear stress we know curvatures do have an impact 
on plaque formation in the following years where it is 
important to minimize the distortion of the natural ves-
sel course post stent or scaffold implantation. As vascu-
lar geometry is the most important determinant of local 
wall shear stress, any beneficial effect on the conform-
ability of the blood vessel might have clinical implica-
tions. Studies have demonstrated that low wall shear 
stress promotes atherosclerosis and plaque progression 
in native arteries [22] and greater intimal hyperplasia 
Fig. 4  Change in curvature post 
treatment in BRS and MPS. 
This boxplot illustrates the 
difference in median diastolic 
curvature post treatment in the 
BRS compared to the MPS 
group
Fig. 5  Maximum compressive force of ABSORB Cohort B scaffold 
and XIENCE V stent. This figure shows the maximum compres-
sive force applied to deflect the ABSORB Cohort B and XIENCE 
V 3.0 × 18  mm devices by 1.1  mm using 3 point- bend test (n = 5). 
Statistical analysis yielded p = 0.004 using One- way ANOVA and 
Tukey- Kramer HSD. Tests were performed by and data are on file 
at Abbott Vascular. (Reprinted from EuroIntervention Supplement 
(2009) Vol.5 Supplement F; Oberhauser JP, Hossainy S, Rapoza RJ. 
Design principles and performance of bioresorbable polymeric vascu-
lar scaffolds. F15-22, Copyright, with permission from Europa Digi-
tal and Publishing)
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after stent deployment [23]. Metallic stents deployed 
in curved porcine coronary arteries were noted to cause 
vessel straightening in the stented segment and increased 
curvature at the stent edges [2]. A study by Gyongyosi 
et  al. had further showed that a longitudinal straighten-
ing of stents is an additional predictor of major adverse 
events [24]. There are possible physiological and clini-
cal benefits arising from the improvement in conform-
ability in the BRS. An increased conformability of the 
BRS platform may result in physiological wall shear 
stress at the stent edges due to less vessel distortion. 
This may translate to clinical benefits such as reduced 
risk of scaffold edge restenosis. However, the clinical 
benefits associated with better conformability still needs 
further evaluation. This has become more relevant in 
the setting of recent data that showed a potential lack of 
benefits up to 3 years [25] particular certain lesion sub-
sets such as smaller vessels with the BRS compared with 
best in class DES, with the BRS showing either similar 
or increased risk of TLR and increased risks of scaffold 
thrombosis compared to DES [26, 27].
Stent flexibility (and conformability) is also one of 
the key determinants of stent fracture, a common cause 
of late stent failure. Hinge motion (i.e. rocking back and 
forth on a bend) was one of the factors that can increase 
the risk of stent strut fracture. Our results suggest that 
there is a subtle but certain cyclic change of curvature 
after device implantation in both groups. Although there 
is no difference between groups, one can speculate that 
this cyclic movement repeating greater than 86,400 
times a day (based on average heart rate of 60 beats 
per minute) can cause mechanical failure at the metal-
lic struts. In a study looking at predictors of stent frac-
ture, stent fracture was identified in 2.9% of 1339 lesions 
treated with the  XIENCER stent in only 6–9 months after 
placement [28]. In that study, the three major determi-
nants of stent fracture in order of importance were hinge 
motion, ostial location and tortuosity. Since the BRS is 
programmed to get dismantled in the due course of the 
bioresorption, this might cause fewer problems with 
BRS than with MPS.
The impact of procedural factors such as predilation 
on conformability is still unknown. Although lesion pre 
and postdilation may potentially impact on outcome by 
its impact on lesion expansion (concentricity, eccen-
tricity, final MLD/MLA, remaining DS% and AS%), 
changes in curvature is ultimately mostly influenced by 
the remaining implanted material characteristics and 
the design of the stent/scaffold (Number of longitudinal 
connectors). In clinical practice this is manifested by 
the straightening of the vessel during balloon inflations 
and increase in vessel curvatures directly after balloon 
deflation.
Limitations
We acknowledge the following limitations. The study is 
non-randomized and population in each group is rela-
tively small. 2D angiographic analysis may also not be the 
most optimal imaging modality to assess the geometry of 
coronary vessels. However the differences between the pre 
and post treatment angiographic views were less than 10°, 
indicating that the analysis were mainly performed in the 
same angiographic view. In addition, the precise impact 
of subsequent procedural steps (predilation, stent implan-
tation, postdilation) on vascular curvature could not be 
entirely captured due to the inherent retrospective nature 
of our study and there was no specific protocol for opera-
tors to include the necessary angiographic or cinefluro-
scopic projections. Potentially this issue is best addressed 
in a future prospective study with dedicated research pro-
tocol ensuring the angiographic projections are obtained at 
the procedural steps of predilation, stent implantation and 
postdilation.
Conclusion
In the deployment of long coronary scaffolds/stents (28 mm 
in length), bioresorbable scaffolds provides better conform-
ability compared with MPS. The findings of this study and 
its clinical significance merits further evaluation.
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